drugset / Trial / NCT06863662

Efficacy and Safety of Etoricoxib/Tizanidine Versus Etoricoxib for Acute Low Back Pain Associated to Muscle Spasm

NCT06863662

Phase 3 Completed 136 enrolled Laboratorios Silanes S.A. de C.V.
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a Phase III, longitudinal, multicenter, randomized, double-blind clinical trial. The aim of the study is to evaluate the efficacy and safety of a fixed-dose combination of etoricoxib and tizanidine compared to etoricoxib alone in patients with acute low back pain associated with muscle spasms.

Timeline

Start
2024-09-18
Primary completion
2025-09-26
Completion
2025-12-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Etoricoxib Small molecule 120 mg Oral
Subject Tizanidine Small molecule 4 mg Oral

Indications

No indication recorded.